A Business at a Glance
0 of 5 daily views used (5 remaining). Sign up free for 10 daily views, or try AAPL for a full preview.
OUR COMPANY We are a commercial stage biopharmaceutical company developing and commercializing innovative vaccines to help protect the world against infectious diseases. We are currently focused on our efforts to drive long-term shareholder value by maximizing utilization of our HEPLISAV-B® hepatitis B vaccine, expanding our own portfolio of innovative vaccine candidates leveraging our proven CpG 1018® adjuvant technology, and identifying strategic opportunities to accelerate growth through both commercial and research collaborations. HEPLISAV-B [Hepatitis B Vaccine (Recombinant), Adjuvanted] Our first marketed product, HEPLISAV-B [Hepatitis B Vaccine (Recombinant), Adjuvanted], is approved in the United States ("U.S."), the European Union ("EU") and the United Kingdom for prevention of infection caused by all known subtypes of hepatitis B virus ("HBV") in adults aged 18 years and older. HEPLISAV-B is the only two-dose hepatitis B vaccine for adults approved in the U.S.
| Metric | TTM | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|---|
| Revenue | 331M | 277M | 232M | 723M | 439M | 47M |
| Net Income | -43M | 27M | -6.4M | 293M | 72M | -75M |
| EPS | $-0.37 | $0.20 | $-0.05 | $1.97 | $0.57 | $-0.78 |
| Free Cash Flow | 81M | 60M | 96M | 56M | 326M | -96M |
| ROIC | 4.4% | 4.5% | -1.0% | 133.9% | 59.8% | -31.5% |
| Gross Margin | 83.2% | 82.2% | 78.4% | 63.7% | 64.3% | 94.6% |
| Debt/Equity | 0.56 | 0.42 | 0.41 | 0.44 | 1.15 | 3.66 |
| Dividends/Share | $0.00 | - | - | - | - | - |
| Operating Income | 10M | -4.1M | -37M | 284M | 134M | -68M |
| Operating Margin | 3.2% | -1.5% | -15.9% | 39.2% | 30.6% | -146.9% |
| ROE | -8.1% | 4.5% | -1.0% | 50.4% | 32.4% | -128.2% |
| Shares Outstanding | 117M | 137M | 128M | 149M | 127M | 96M |
DYNAVAX TECHNOLOGIES CORP passes 4 of 9 quality checks, suggesting mixed fundamentals.
On a free-cash-flow basis, the stock trades at 22.6x vs a median of 23.2x. The company's 5-year average ROIC is 33.1% with a gross margin of 76.6%. Total shareholder yield (buybacks) is 11.1%. At current prices, the estimated annualized return to fair value is -10.0%.
DYNAVAX TECHNOLOGIES CORP (DVAX) has a 5-year average return on invested capital (ROIC) of 33.1%. This indicates strong capital allocation and a potential competitive advantage.
DYNAVAX TECHNOLOGIES CORP (DVAX) has a market capitalization of $1.8B. It is classified as a small-cap stock.
DYNAVAX TECHNOLOGIES CORP (DVAX) does not currently pay a regular dividend. However, the company returns capital to shareholders through share buybacks, with a buyback yield of 11.05%.
DYNAVAX TECHNOLOGIES CORP (DVAX) operates in the Pharmaceutical Preparations industry, within the Healthcare sector.
DYNAVAX TECHNOLOGIES CORP (DVAX) reported annual revenue of $277 million in its most recent fiscal year, based on SEC EDGAR filings.
DYNAVAX TECHNOLOGIES CORP (DVAX) has a net profit margin of 9.9%. This is a modest margin.
DYNAVAX TECHNOLOGIES CORP (DVAX) generated $60 million in free cash flow in its most recent fiscal year. Positive free cash flow supports dividends, buybacks, and debt reduction.
DYNAVAX TECHNOLOGIES CORP (DVAX) has a debt-to-equity ratio of 0.42. This indicates a conservatively financed balance sheet.
DYNAVAX TECHNOLOGIES CORP (DVAX) reported earnings per share (EPS) of $0.20 in its most recent fiscal year.
DYNAVAX TECHNOLOGIES CORP (DVAX) has a return on equity (ROE) of 4.5%. This indicates moderate shareholder returns.
DYNAVAX TECHNOLOGIES CORP (DVAX) has a 5-year average gross margin of 76.6%. This high margin suggests strong pricing power and a potential competitive moat.
The Ledger Terminal provides 15 years of financial data for DYNAVAX TECHNOLOGIES CORP (DVAX), sourced directly from SEC EDGAR filings. This includes income statements, balance sheets, cash flow statements, and key financial ratios.
DYNAVAX TECHNOLOGIES CORP (DVAX) has a book value per share of $4.37, based on its most recent annual SEC filing.
No recent press releases.